Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

In the trials, tirzepatide (Mounjaro, Eli Lilly) was associated with a mean weight loss of about 26% in both trials, with a safety profile similar to that previously reported in other SURMOUNT ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

The 'twincretin' tirzepatide (Mounjaro) met its primary endpoints compared with placebo in the SURMOUNT-2 trial, designed to test weight loss efficacy, in top-line results reported by Lilly.

Eli Lilly’s trending weight loss candidate tirzepatide has scored its second pivotal trial win—once again with impressive results.. Also known as Mounjaro when marketed as a Type 2 diabetes ...

Weight loss results on Zepbound vary between people, but clinical trials have reported weight loss of more than 10% of body weight in people taking tirzepatide for 72 weeks (1.5 years).

Overall, 86.0% of participants completed the primary trial treatment period (88.4% to 89.8% across the tirzepatide groups and 77.0% in the placebo group) and 81.9% adhered to the treatment or ...

We conducted the SURPASS-2 trial (A Study of Tirzepatide [LY3298176] versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants with Type 2 Diabetes) to compare the efficacy and ...